
Scan other high-yield opportunities by lining up Altria Group's income profile against our hand picked 6 dividend fortresses in the current market.
To own Altria Group, you need to believe that high margin tobacco cash flows and a gradual shift into smoke free products can support earnings while cigarette volumes stay under pressure. The analyst consensus Narrative on Simply Wall St leans on on! and on! PLUS gaining traction and pricing across Marlboro and discount brands holding up. The richer dividend and recent share price strength do not change that core thesis.
The near term swing factor is execution in oral nicotine pouches and managing consumer trade down into discount cigarettes. Key risks sit around on! PLUS profitability after softer oral tobacco income, as well as legal and regulatory scrutiny that could bring extra cost. The latest dividend lift reinforces the income story but does not remove those pressures.
The recent 4.7% dividend increase and yield above 5% is the announcement that matters most for this story. It ties directly into a case that already relies heavily on cash returns, with about US$3.6b in dividends and US$335m of buybacks in the first half of 2026. That cash profile supports per share earnings even if top line progress is modest.
For you as a shareholder, the question is whether Altria Group can keep funding this payout while investing in areas the analyst consensus Narrative on Simply Wall St highlights, such as on! PLUS expansion and FDA approved pouches. Earnings forecasts that point to growth of around 5.33% a year and high forecast return on equity help frame that debate, but the legal, regulatory and consumer mix risks remain central to the outlook.
Altria Group's narrative projects US$21.3b revenue and US$10.0b earnings by 2029. This relies on revenue declining 2.2% a year and an earnings increase of about US$1.9b from current earnings of US$8.1b.
Uncover why Altria Group's fair value indicates an 8% potential downside to its current price, a premium that may not hold.
One alternate view focuses less on Altria Group’s dividend and more on the risk that oral tobacco profits stay under pressure. The most cautious analysts were only penciling in about US$20.8b of revenue and US$9.5b of earnings by 2029 before this news. That is a much tougher narrative. Use it as a prompt to compare several viewpoints and then decide which numbers feel realistic to you.
Explore 5 other Altria Group fair value estimates, including one that suggests as much as 26% downside from the current price!
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so consider doing your own research and analysis.
If the Altria Group story has sharpened your view on income, risk and earnings quality, it can be useful to cast a wider net and compare it against other companies that share some of those traits but approach them in very different ways.
To broaden your watchlist in a focused way, consider using the Simply Wall St Screener to hunt for opportunities that match your own tolerance for volatility, balance sheet strength and dividend reliance.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com